StockData

Hims & Hers Health vs Teladoc Health

HIMS and TDOC side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HIMS and TDOC compare

Hims & Hers Health is the larger company, worth 2.7 times as much as Teladoc Health ($4.3B against $1.6B).

Hims & Hers Health grew revenue faster over the last twelve months (28.0% versus −2.4% for Teladoc Health).

Hims & Hers Health keeps more of each dollar of sales as profit, with a net margin of −5.5% compared with −6.3% at Teladoc Health.

Hims & Hers Health scores higher on the StockData Score (9 against 4 for Teladoc Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHIMSTDOC
Size and price
Market cap$4.3B$1.6B
Share price$18.56$8.70
Change, 1 year−48.5%23.1%
Change, 5 years170%−92.1%
Beta (5Y)2.191.25
Employees1,0465,600
StockData Score
Total score9 (better)4
Valuation score03 (better)
Growth score3 (better)0
Performance score2 (better)1
Health score4 (better)0
Dividend score00
Valuation
P/S1.7×0.6× (better)
P/B13.4×1.2× (better)
P/FCF70.4×6.1× (better)
FCF yield1.4%16.5% (better)
Fair value$6.46$14.83
Margin of safety−187%41.3% (better)
Growth
Revenue growth (TTM)28.0% (better)−2.4%
Revenue growth, 5Y average73.6% (better)18.3%
Net income growth (TTM)−173%–
EPS growth (TTM)−179%–
Profitability
Gross margin68.4%68.6% (better)
Operating margin−6.0% (better)−6.6%
Net margin−5.5% (better)−6.3%
FCF margin2.4%10.6% (better)
Return on equity−32.0%−11.5% (better)
Return on invested capital–−23.2%
Financial health
Debt / equity0.00–
Interest coverage–−8.0×
Current ratio0.93 (better)0.87
Altman Z-score1.21 (better)−7.10
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions67.1%83.6%
Held by insiders10.9%0.71%
Insider net buying, 12 months−$17.1M−$2.7M (better)
Short interest, % of float24.9%17.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.